SCHEMBL16629871

SCHEMBL16629871

COc1cccc(C(O)CN)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
SLC6A3 Q01959 2/20 0.43
KCNH2 Q12809 1/20 0.43
NFKB1 P19838 2/20 0.41
BLM P54132 2/20 0.41
PMP22 Q01453 1/20 0.41
ADRA2A P08913 2/20 0.39
ADRA1A P35348 2/20 0.39
TAAR1 Q96RJ0 3/20 0.37
HRH1 P35367 1/20 0.36
HTR3A P46098 1/20 0.36
TSHR P16473 1/20 0.36
HIF1A Q16665 1/20 0.36
PNMT P11086 1/20 0.36
APEX1 P27695 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23888635 0.84 CYP3A4 (0.44) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL8865877 0.80 CYP3A4 (0.45) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL38661913 0.78 CYP3A4 (0.44) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL4196024 0.78 CYP3A4 (0.44) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL4911914 0.77 NOS2 (0.42) CYP3A4NFKB1BLMADRA2AADRA1A
SCHEMBL3724966 0.77 NOS2 (0.42) CYP3A4NFKB1BLMADRA2AADRA1A
SCHEMBL6321507 0.77 NOS2 (0.42) CYP3A4NFKB1BLMADRA2AADRA1A
SCHEMBL1439436 0.76 PDCD1LG2 (0.42) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL1439439 0.76 PDCD1LG2 (0.42) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL29337164 0.76 TAAR1 (0.43) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 EP disclosed
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 EP disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CYP3A4 1226/4885CYP2D6 1692/4885SLC6A2 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.